Physician Assistant Program year 2025 Reported 2022–2025 Source: CMS Open Payments, 2026 publication

Lindsay Odonohoe

Physician Assistant Bensalem, PA Physician Assistant

NPI 1902532880 CMS profile 11369271

3101 Bristol Rd Ste 4, Bensalem, PA 19020

Open in the dashboard

General payments

$13,740

510 records reported · program years 2022–2025

Research payments

$0

Paid to them · None reported · program years 2022–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Lindsay Odonohoe of Bensalem, PA is reported in the CMS Open Payments database as having received $13,740 across 510 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 98th percentile of Physician Assistant profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

4 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $5,844 140
2024 General $3,667 183
2023 General $3,481 159
2022 General $748 28

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Lindsay Odonohoe
  • Physician Assistant median
  • Middle half of Physician Assistant
  • National median

In program year 2025, general payments to Lindsay Odonohoe were reported at $5,844. Among 68,903 Physician Assistant profiles paid that year, the median was $184 and the middle half received between $57 and $620.

Show as a table
Year Lindsay Odonohoe Physician Assistant median Middle half National median
2019 $0 $34 $17–$122 $163
2020 $0 $33 $16–$78 $114
2021 $0 $132 $37–$438 $132
2022 $748 $155 $48–$522 $149
2023 $3,481 $167 $52–$557 $160
2024 $3,667 $178 $55–$600 $164
2025 $5,844 $184 $57–$620 $169

Breakdown

Who paid General payments · program years 2022–2025
  1. Janssen Biotech, Inc. $5,580 130 payments
  2. AbbVie, Inc. $1,312 91 payments
  3. LEO Pharma Inc. $1,059 39 payments
  4. Regeneron Healthcare Solutions, Inc. $760 30 payments
  5. Sun Pharmaceutical Industries Inc. $725 26 payments
  6. Genzyme Corporation $574 18 payments
  7. Lilly USA, LLC $563 32 payments
  8. E.R. Squibb & Sons, L.L.C. $488 20 payments
  9. Novartis Pharmaceuticals Corporation $376 16 payments
  10. Amgen Inc. $242 12 payments
  11. Other $2,061 96 payments

Every payment, record by record

What the payments were for General payments · program years 2022–2025
  1. Food and Beverage $10,625 503 payments
  2. Consulting Fee $2,700 1 payment
  3. Education $416 6 payments
Products named General payments · program years 2022–2025
  1. TREMFYA $5,807 132 payments
  2. ADBRY $911 37 payments
  3. DUPIXENT Immunology $803 28 payments
  4. SKYRIZI $785 53 payments
  5. DUPIXENT Inflammation And Immunology $516 23 payments
  6. TALTZ $510 29 payments
  7. SOTYKTU $488 20 payments
  8. RINVOQ $391 25 payments
  9. OLUMIANT $365 22 payments
  10. ILUMYA $314 12 payments
  11. Other $3,538 181 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 23 drugs

Part D claims

1,458

Median for Physician Assistant: 241

Drug cost

$268,686

Median for Physician Assistant: $4,110

Branded share of claims

2.5%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Skyrizi Pen Risankizumab-Rzaa Brand 11 $228,247
Clobetasol Propionate Generic 249 $12,881
Tacrolimus Generic 32 $6,962
Ketoconazole Generic 226 $3,461
Calcipotriene Generic 15 $2,268
Triamcinolone Acetonide Generic 161 $2,071
Selenium Sulfide Generic 183 $2,007
Minocycline Hcl Generic 65 $1,752
Fluocinolone Acetonide Generic 38 $1,736
Tretinoin Generic 28 $1,411

The 10 drugs with the highest cost, of 23 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 26 billing codes

Paid by Medicare

$151,720

Of which drugs: $24

Medicare patients

733

Average age 74

Services billed

3,432

471 women, 262 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 69%
Arthritis 45%
Ischemic heart disease 26%
Diabetes 20%
Cancer 19%
Osteoporosis 18%
Atrial fibrillation 15%
Chronic kidney disease 15%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 13 31 $24

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 26 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
TREMFYA
  • Janssen Biotech, Inc. $832
$832 — —
SKYRIZI
  • AbbVie, Inc. $383
$383 11 —
DUPIXENT
  • Regeneron Healthcare Solutions, Inc. $212
  • GENZYME CORPORATION $144
$356 — —
ADBRY
  • LEO Pharma Inc. $310
$310 — —
Otezla
  • Amgen Inc. $168
$168 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 26 with Patron

Records

510 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant in Pennsylvania

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record